Skip to main content

ICH E8 General considerations for clinical trials (CPMP/ICH/291/95)

 ICH E8, titled "General Considerations for Clinical Trials," is a guideline developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The reference number for this guideline is CPMP/ICH/291/95. ICH E8 provides overarching principles and recommendations for the planning, conduct, and reporting of clinical trials. It serves as a foundational guideline that helps ensure the quality and integrity of clinical trial data. Here's an elaboration of ICH E8:


1. Purpose:

The primary purpose of ICH E8 is to provide a framework for the design, conduct, analysis, and reporting of clinical trials. It emphasizes the importance of robust trial design and data quality to support regulatory decision-making.

2. Applicability:

ICH E8 is applicable to all phases of clinical trials conducted to support the development and registration of pharmaceutical products for human use, including investigational drugs, biologics, and medical devices.

3. Guiding Principles:

The guideline is based on several fundamental principles, including the need for scientific rigor, ethical conduct, protection of human rights and well-being, and the reliability and credibility of trial data.

4. Trial Design:

ICH E8 emphasizes the importance of a well-designed clinical trial, including clear objectives, appropriate endpoints, and a statistical plan to assess the primary and secondary outcomes.

5. Risk-Benefit Assessment:

The guideline highlights the significance of assessing the risk-benefit profile of the investigational product throughout the trial. This assessment is crucial for determining the overall acceptability of the product's benefits and risks.

6. Ethical Considerations:

ICH E8 underscores the need for ethical conduct in clinical trials, including obtaining informed consent from trial subjects and ensuring that trials are conducted in accordance with ethical principles and regulatory requirements.

7. Data Quality and Integrity:

The guideline emphasizes the importance of data quality and integrity. It provides recommendations for data collection, handling, and verification to ensure the accuracy and reliability of trial data.

8. Safety Reporting:

ICH E8 includes recommendations for the collection, reporting, and assessment of adverse events and serious adverse events during the trial. Timely and accurate safety reporting is crucial.

9. Protocol Amendments:

The guideline provides guidance on making amendments to the trial protocol. It emphasizes the importance of protocol amendments being documented, approved by ethics committees, and communicated appropriately.

10. Statistical Considerations:

- ICH E8 discusses statistical considerations in clinical trials, including sample size determination, randomization, and statistical analysis methods. These aspects are critical for the validity of trial results.

11. Regulatory Submissions:

- Clinical trial data collected in accordance with ICH E8 are essential for regulatory submissions, such as New Drug Applications (NDAs) or Marketing Authorization Applications (MAAs). The guideline provides recommendations for the presentation of trial data in these submissions.

12. Quality Control and Quality Assurance:

- The guideline emphasizes the importance of quality control and quality assurance measures to ensure the integrity of trial conduct and data.

13. Patient Recruitment and Retention:

- ICH E8 acknowledges the importance of effective patient recruitment and retention strategies to ensure the successful completion of clinical trials.


In summary, ICH E8 provides a comprehensive framework for the planning, conduct, analysis, and reporting of clinical trials. Compliance with this guideline is essential for pharmaceutical companies, investigators, and regulatory authorities to ensure the quality, reliability, and ethical conduct of clinical trials, ultimately leading to informed regulatory decisions and the development of safe and effective pharmaceutical product

Labels:

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more